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Nuclear magnetic resonance (NMR) spectroscopy is a pivotal method for structure-based and fragment-
based lead discovery because it is one of the most robust techniques to provide information on protein
structure, dynamics and interaction at an atomic level in solution. Nowadays, in most ligand screening
cascades, NMR-based methods are applied to identify and structurally validate small molecule binding.
These can be high-throughput and are often used synergistically with other biophysical assays. Here, we
describe current state-of-the-art in the portfolio of available NMR-based experiments that are used to aid
early-stage lead discovery. We then focus on multi-protein complexes as targets and how NMR spec-
troscopy allows studying of interactions within the high molecular weight assemblies that make up a
vast fraction of the yet untargeted proteome. Finally, we give our perspective on how currently available
methods could build an improved strategy for drug discovery against such challenging targets.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
A major purpose of academic and pharmaceutical drug devel-
opment research is to identify natural or synthetic molecules that
interact both strongly and speciﬁcally with a given biomolecule to
produce an anticipated biological response (Wells and McClendon,
2007; Zorn and Wells, 2010). The majority of current drug targets
are G-protein-coupled receptors, nuclear receptors, ion channels
and enzymes; all of which are targets of previously adopted
pharmacology-driven approaches (Makley and Gestwicki, 2013).
Our understanding of the fundamentals of molecular recognition of
such interactions has evolved as a result of methodological de-
velopments and technological breakthroughs over the years. The
post-genomic era transformed our approach and ability to study
the proteomes of many organisms and as a result “target-ﬁrst
pharmacology-second” strategies were established as a dominant
trend (Fry, 2006; Hopkins and Groom, 2002; Makley and Gestwicki,
2013; Nú~nez et al., 2012; Surade and Blundell, 2012; Wells and
McClendon, 2007). Recent molecular and structural biology-based
and genome-based approaches have enabled identiﬁcation of a
plethora of biologically relevant proteineprotein interactionsr Ltd. This is an open access article(PPIs), many of which are established or potential targets for small
molecule chemical probes and drugs (Cummings and Hamilton,
2010; Fry, 2006; Fuller et al., 2009; Higueruelo et al., 2009; Jubb
et al., 2012; Nooren and Thornton, 2003; Thangudu et al., 2012;
Wells and McClendon, 2007). Multi-protein complexes are
responsible for numerous important biological processes and are
one of the most preponderant classes of biologically active mac-
romolecules. Targeting of PPIs within suchmulti-protein complexes
shows promising therapeutic value but presents a number of
challenges when compared with more canonical drug targets such
as orthosteric enzyme active sites (Nooren and Thornton, 2003;
Smith and Gestwicki, 2012). Moreover the concept of ‘drugg-
ability’ (or ligandability) has become a rational tie for target se-
lection, as many proteins remain to be successfully obtained,
manipulated and efﬁciently targeted (Drewry and Macarron, 2010;
Makley and Gestwicki, 2013; Wells and McClendon, 2007; Edfeldt
et al., 2011).
Drug discovery has evolved in the last decades and within this
realm, structure-based drug design (SBDD) (Blundell, 1996) and
fragment-based lead discovery (FBLD) (Hajduk and Greer, 2007;
Shuker et al., 1996) have been emerging as powerful methods for
discovering high-afﬁnity ligands for targeting proteins. FBLD has
yielded a number of successful cases and these have proven to be
useful for drug discovery, (Bollag et al., 2010; Drysdale and Brough,under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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offering indeed clinical candidates for therapeutic purposes. In or-
der to undertake an efﬁcient chemical space exploration for lead
development, FBLD uses ‘fragments’ which are low molecular
weight compounds with somehow minor complexity that interact
weakly, yet efﬁciently, with a macromolecular target (Mashalidis
et al., 2013; Rees et al., 2004). The ‘fragment’ concept has been
extensively argued and several guidelines for library design and
biophysical techniques for screening cascades have been proposed
to broaden the scope and applications of this approach on drug
discovery. By yielding suitable starting chemical matter with high
ligand efﬁciencies (LEs) (Kuntz et al., 1999; Zorn and Wells, 2010)
FBLD has the potential to aid effective targeting of less well-deﬁned
ligand binding pockets within the so-called ‘undruggable’ protein
targets.
Historically FBLD and NMR spectroscopy have always been
closely connected (Dalvit et al., 2003; Diercks et al., 2001; Huth
et al., 2005; Pellecchia et al., 2008, 2002; Shuker et al., 1996). The
advent of structure-activity relationship (SAR) by NMR (Shuker
et al., 1996) methodology brought FBLD to life, setting a new hall-
mark in drug discovery. Due to NMR spectroscopy's wide scope and
inherent ability to detect weakly binding fragments (single digit
mM Kds), its entanglement with FBLD has grown and appears to be
stronger than any other exhibited by alternative FBLD-assisting
techniques (Ludwig and Guenther, 2009; Rees et al., 2004;
Roberts, 2000). NMR spectroscopy's ability to detect and charac-
terise fragment binding has placed it in a preeminent position for
qualitatively detecting if interactions are happening and where
these interactions are taking place in the protein. In addition, the
binding modes can also be established (Becattini and Pellecchia,
2006; Constantine et al., 2006; Guan et al., 2013). Moreover, by
directly observing binding events NMR experiments are less prone
to the kind of false-positive hit identiﬁcation and artefacts found in
other screening techniques.
NMR spectroscopy's ability to analyse structure, interactions
and dynamics has been evolving in the direction of its main limi-
tation, the size of molecular complexes (Fernandez and Jahnke,
2004; Mittermaier and Kay, 2006; Pervushin et al., 1997). In this
review we focus our attention on the available techniques and
successful literature examples of NMR spectroscopy's contribution
to structure-based targeting of multi-protein complexes. It is not
our aim to be exhaustive on all the NMRmethods available, instead
to highlight how available tools can be used when handling large
complexes. Emphasis will be made on current possibilities and how
recent methodological developments are moving NMR spectros-
copy in the direction of high molecular weight proteins and their
complexes. Such biomolecules are prevalent players in key bio-
logical signalling processes and constitute attractive new drug
targets against many diseases. Since NMR isotope-active protein
expression is a requisite, we also highlight currently available
methods to yield good spectra in challenging systems. The review
will conclude with a discussion on available technology and new
frontiers for targeting multi-protein complexes for drug discovery
using both structural and dynamical information provided by NMR
spectroscopy.
2. Existing NMR approaches for hit generation and
characterisation
Theoretically, NMR spectroscopy parameters may serve to
interrogate molecular interactions and binding. Sensitivity how-
ever limits the dynamic range of NMR observables and only a
subset of such parameters is routinely monitored. Changes in
chemical-shift, nuclear overhauser effects (NOEs), relaxation times
or diffusion constants are often informative-richmeasures acquiredfrom NMR experiments (Hajduk et al., 2005; Harner et al., 2013;
Jahnke, 2007; Lepre, 2011; Pellecchia et al., 2002). These experi-
ments coherently identify binding events by gauging two main
categories: small molecule ligand resonances or, alternatively,
resonances of the protein(s) e if size of the target protein permits
both ligand-based and target-based approaches can be synergisti-
cally used to provide a complete picture for an interaction. None-
theless, NMR spectroscopy's hit generation and characterisation in
lead development is still a very active ﬁeld and continuously
expanding (Barrett et al., 2013).
2.1. Ligand-based NMR
Experiments based on the resonances of the small molecule
(ligand or fragment) observe only unbound ligand. Nonetheless,
these are also informative of the ligand's history if their dissociation
is within the timescale of these experiments (100e1000 ms). In a
mixture of protein(s) and ligand(s) the effects of binding will be
transferred to the unbound ligand because during the time where
the ligand is bound to the protein it will not behave as a small
molecule as far as NMR observables goes. During this bound period
the ligand behaves like the protein e it now tumbles slowly, it
portrays faster relaxation and large negative NOEs. Differences in
NMR observables of ligand spectra acquired in the presence and
absence of protein can therefore disclose binding (Sledz et al.,
2012).
The major beneﬁt of monitoring the ligand resonances is the
absence of need to isotopically enrich the target
macromolecule (Diercks et al., 2001). Additionally, the size of the
macromolecular binding partner has no upper limit restriction. The
binding phenomena can be observed in protein concentrations as
low as 5 mM and the throughput of these experiments can be
increased by cocktailing several ligands simultaneously. A common
limiting step in ligand-based NMR screening is sometimes the
compound's solubility in aqueous buffers and usually concentra-
tions higher than 200 mM are a requisite for successful NMR
method application.
Ligand-based screening techniques are extensively reviewed.
Some techniques are more popular and widely used than others.
Transfer NOE-type experiments such as saturation transfer differ-
ence (STD) (Mayer and Meyer, 2001, 1999) and water ligand-
observed spectroscopy (WaterLOGSY) (Dalvit et al., 2000) occupy
the top of the list for two of the most widely applied NMR tech-
niques in hit generation (Fig. 1a, b, respectively). Both methods are
capable of detecting weak interactions and the bigger the target the
larger the difference between the NOE strength and sign, depicting
clear binding proﬁles much better. While STD experiments saturate
protein resonances directly, WaterLOGSY relies on saturation
transfer from bulk water to any bound ligand directly or indirectly
via protein by intermolecular spin diffusion.
Ligand-based NMR binding assays have proven to be robust hit
generation methodologies and the current available list features
not only 1H schemes but also heteronuclear detection methodolo-
gies (19F or 31P). In these cases, the resulting spectra are much
simpler and easy to interpret and these techniques are gaining
popularity in fragment screening campaigns. One such example is
the binding assay known as ﬂuorine chemical shift anisotropy and
exchange for screening (FAXS) (Dalvit et al., 2003; Dalvit and
Vulpetti, 2012) (Fig. 1c). Here, the observed 19F transverse relaxa-
tion R2 in the absence and presence of the protein are indicative of
an interaction. Although the detection increases by working at
stronger magnetic ﬁelds this method is validated in ﬁelds as low as
400MHz. The set-up requirements make this technique suitable for
wide use and beneﬁting from high sensitivity FAXS can reliably
detect fragments starting at very low afﬁnity.
Fig. 1. Representative NMR techniques used for hit generation. The left panel depicts the protein and the principle of the technique, the middle panel shows examples of fragment
structures from the screening library that can be analysed by each technique, and the right panel shows the different spectral behaviour for hits (green resonances) and non-binders
(red resonances).
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ally low for NMR techniques such as target immobilized NMR
screening (TINS) (Vanwetswinkel et al., 2005) (Fig. 1d) which al-
lows using the same sample for more than 2000 fragments. This
method therefore reduces signiﬁcantly the amount of target pro-
tein to be used in a screening campaign and exhibits a throughput
of 1500 compounds per 4 days. The TINS approach has been shown
to generate and validate hits on a variety of targets, making it a very
attractive option to start a hit discovery process. Another alterna-
tive to reduce the protein requirements is using spin-labels. Spin
labels attached to protein side chain as a tool to identify interacting
compounds (SLAPSTIC) (Jahnke, 2002; Jahnke et al., 2001) (Fig 1e)
requires selective labelling of the target residues (e.g. lysine, tyro-
sine, cysteine, histidine or methionine) or the use of a
paramagnetically-tagged known binding ligand. As a requirement
at least one residue should be as close as possible to the binding
site, but without being involved in the interaction. The para-
magnetic relaxation rates are higher than the diamagnetic rates on
a given target, and this allows a reliable detection of hits as low as
50 times less protein. Moreover, the discrimination of hits and non-
hits becomes so evident that it is possible to automate the analysis
of SLAPSTIC experiments.
2.2. Protein-based NMR
Protein resonances are information-rich NMR observables that
can be used to reveal structure, function and dynamics under most
circumstances. With the possibility to study both solution and
solid-state samples NMR offers one of the most robust methods for
detecting and characterising physical interactions. In FBLD it is well
documented how useful this data can be. Direct assessment of
protein resonances unveils where on the protein an interaction
may occur and also how this interaction is made.
Protein-based NMRmethods historically gave birth to fragment-
based screening approaches. In order to map which speciﬁc resi-
dues in the sequence, and ultimately the structure, are involved in
the interaction, a high level of backbone amide resonance assign-
ment is necessary. This requires double isotope-labelling and
additional experimentation, usually from triple-resonance ap-
proaches. Although there are restrictions imposed by the target's
molecular weight (around 40 kDa) nowadays there are several
relaxation-optimized NMR techniques to tackle the relaxation and
linewidth problems accompanying high molecular weight targets.
Additional improvements on the experimental time to undertake
these types of experiments have been making NMR a high
throughput approach strengthening its position in hit generation
and characterization.
The most common protein-based NMR technique is the 2D
1He15N heteronuclear single quantum correlation (HSQC)
(Bodenhausen and Ruben, 1980) of 15N-labelled proteins. Since this
experiment observes the amide NH groups, which become chem-
ically unique in the context of the protein's tertiary structure, it
allows monitoring binding events in a residue speciﬁc manner.
Using 2D HSQC one can collect the spectra in the absence and in the
presence of small-molecule compounds or other target proteins.
This simple approach allows obtaining chemical shift perturbation
(CSP) (Williamson, 2013) data. A comparison of 2D 1He15N HSQC's
in the presence and absence of the putative interaction partner
discloses binding events. These can be monitored by following the
shifting residues (when in a fast exchange regime) or decrease in
intensity (and may be even disappearance and appearance again) if
in a slow exchange regime. Perturbed residues are usually identi-
ﬁed as those which exhibit changes beyond one or two standard
deviations. If the protein structure is known, it is possible to
immediately identify the binding site by mapping these residuesonto the protein structure. In order to eliminate the possibly biased
cut-off to set when analysing CSPs, one can use SAMPLEX.
(Krzeminski et al., 2010) Such an approach guarantees amuchmore
unbiased selection of the relevant CSPs by automating this selection
and predicting statistically signiﬁcant residues that should have
shown CSPs (either because of experimental errors or because they
are prolines), based on the three-dimensional structure of the
target.
The chemical shift perturbation assay has been used extensively
to identify binding sites of small molecules. This approach gained
even more popularity when SAR by NMR was introduced in
1996 (Shuker et al., 1996). SAR by NMR (Fig. 2) ﬁrst uses CSP data
fromweakly interacting compounds in order to optimize them for a
given site in the protein. The second step is to ﬁnd adjacent sites in
the proteinwhere another weakly interacting compound is binding
and optimize it as far as possible. The third step is to disclose the
orientation of the bound ligands in order to guide their linkage and
elaboration and maintain this orientation in the ﬁnal compound,
thereby achieving high speciﬁcity to that target. This technique
therefore allows high-afﬁnity ligand elaboration and reduces the
laborious chemical synthesis necessary for such potency.
The SAR by NMR method has facilitated the development of
highly potent and speciﬁc compounds and it continues to be one of
the most popular and successful NMR technique for FBLD (Hajduk
et al., 1999, 2000; Oost et al., 2004; Petros et al., 2010; Sun et al.,
2012).
2.3. Ligand-bound conformation and protein binding sites
identiﬁcation by NMR
Protein and protein-small molecule structure determination
features on many NMR techniques, and this allows binding site
identiﬁcation by mapping the CSPs obtained upon small molecule
titration. However its use is limited to small and medium sized
protein, as it requires backbone and side chain assignment for
structure calculation. Being also a time consuming duty, several
amenable techniques have been contributing to structural infor-
mation on protein-small molecule complexes. This information is
extremely useful to guide further medicinal chemistry hit-lead
optimization campaigns.
Of particular interest are techniques that do not require protein
resonance assignments to obtain structural information. The ma-
jority of these NMR techniques use some intermolecular NOEs to
generate reasonably good protein-small molecule complex models.
NOE matching (Fig. 3a) (Constantine et al., 2006) is one such
method and it is one of the most popular methods aiding drug
design currently. This NMR technique uses 13C-edited and 13C/15N-
ﬁltered HSQC-NOESY spectra to evaluate small molecule binding
poses. Here only 1H assignments of the bound small molecule are
critical and by comparing the experimental above-mentioned
spectra with predicted ones (e.g. from binding poses obtained by
computational docking) it is possible to identify the matches. This
matching is then scored and if sufﬁcient protein-small molecule
NOEs can be measured, informative-rich models can be crafted.
Other popular approaches, like STD and WaterLOGSY-based
ones, also can illustrate small molecule binding mode knowledge
to some extent, by performing careful group epitope mapping
(GEM) around the ligand resonances. However the most robust and
widely used method is the so-called INPHARMA (Fig. 3b) (Sanchez-
Pedregal et al., 2005). The INPHARMAmethod can be used to obtain
relative binding orientations between two ligands that compete for
the same binding pocket on the protein target. Based on the binding
mode of one ligand the competitive ligand's binding epitope are
readily discriminated. Atoms from different small molecules
interacting with the same protein residues will manifest the
Fig. 2. Schematic representation of the stepwise approach of SAR by NMR.
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binding orientations can be derived.
When multiple hits are found for a given protein there is an
opportunity to exploit the theoretical contribution from the linking
coefﬁcient (Borsi et al., 2010; Jencks, 1982; Murray and Verdonk,
2002) to enhance the tethered and validated neighbouring small
molecules into a more potent lead-like compound. This reward is
predominantly due to an entropic gain on tethering adjacent site
binders, which will translate in higher afﬁnity for the binding site.
The structure activity relationships by interligand nuclear Over-
hauser effect (SAR by ILOEs; Fig. 3c) (Becattini and Pellecchia, 2006)
is a 2D NOESY NMR experiment that can be used to detect when
two small molecule ligands bind to a protein next to one another.
The method can also allow the determination of the small mole-
cules binding orientation relative to each other. Only ligands that
bind in relatively close proximity to each other will generate a
signal, allowing identiﬁcation of fragments that may be produc-
tively linked to generate higher afﬁnity bidentate compounds.
Another advantage of the ILOE technique is that it can be applied to
proteins that are too large to study by protein-observed NMR
methods, and even in the absence of the protein structure. As with
many NMR and other biophysical techniques, ILOE may be prone to
compound and protein aggregation artifacts that should be care-
fully taken into account when interpreting the results (Sledz et al.,
2010).
Other NMR based methods are also capable of identifying
protein binding sites both using isotopically labelled or natural
abundance proteins. The ability to identify a binding site using
structural information obtained by Overhauser effects and se-
lective labelling (SOS; Fig. 3d) (Hajduk et al., 2004) is a great
alternative when X-ray or commonly-used NMR methods for
structure-based lead design are not possible. The SOS-NMR
method uses STD NMR spectroscopy on uniformly deuterated
samples except on some speciﬁc residues. Monitoring the STD
spectra on these speciﬁc and differently labelled samples, the
composition of the binding site can be obtained. If three-
dimensional information of the protein is available the identiﬁ-
cation of the binding site is straightforward but even without thisinformation this approach can contribute to a better rationale to
guide later optimization of the small molecule ligand. This can be
achieved by targeting some of the key residues present in the
SOS-NMR revealed binding site.
A relevant approach for initial small molecule validation, both
mapping its binding site and its binding pose, was recently
introduced (Guan et al., 2013). This paramagnetic NMR method is
based on pseudocontact shifts (PCSs) that are used to derive
intermolecular structural restraints (Fig. 3e). This method requires
the attachment of relatively rigid paramagnetic agent-loaded tags
onto the protein of interest. However, once this is achieved and the
integrity and activity of the modiﬁed protein target is veriﬁed,
small molecule PCSs can be obtained from 1D 1H spectra to be used
as docking restraints. Structural information of the protein is
indispensable to obtain the three-dimensional position of the tar-
get's binding site. This promising approach can be applied to non-
isotopically labelled proteins, making it very attractive for hit
validation in fragment screening.
3. Handling large multi-protein complexes: experiences and
lessons using NMR
Large molecular weight targets including multi-subunit protein
complexes exhibit a major limitation both to X-ray and NMR
structural data accomplishment. The application of NMR methods
to high MW proteins is limited primarily by the fact that the line-
widths increase with MW as larger molecules have longer rota-
tional correlation times and as a result much shorter transverse
relaxation times (T2). In hit-to-lead optimization campaigns
structural data is the limiting step to guide a rationale for com-
pound elaboration and introducing chemical modiﬁcations.
Knowledge of the target protein's structure doesn't imply that the
binding of a small molecule hit will be easily validated structurally.
Even if the target protein can be crystallized, soaking sometimes is
not possible and this would mean that co-crystallization and new
crystallization conditions have to be re-iterated. These re-
quirements may be particularly challenging for multisubunit pro-
tein complexes.
Fig. 3. NMR techniques used to study ligand-bound conformation and protein binding sites identiﬁcation. The left panel depicts the protein and the necessary manipulations for
each method. The right panel shows the typical spectra for these techniques.
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means to structural information at atomic resolution for these
types of targets, NMR active isotope labelling is necessary. Size
remains the main limitation, however multiple labelling schemes
and experiments are readily available, making it now possible to
handle assemblies as big as the 1 mega Dalton proteasome
complex (Griswold and Dahlquist, 2002; Mainz et al., 2013).
3.1. Isotopic labelling strategies
Over recent years several labelling strategies have been intro-
duced, helping NMR structural knowledge to be accessible on large
molecular weight targets, multi-domain protein or multi-protein
complexes (homo or heteromeric both symmetrical or
asymmetrical).
When handling large molecular weight targets (>50 kDa) se-
lective labelling (Fig. 4a) is a good option to decrease resonance
overlap on heteronuclear spectra. This is possible by adding just the
desired residues labelled isotopically in the expression
media (Ayala et al., 2009; Tugarinov and Kay, 2004). Although someFig. 4. Isotopic labelling strategies to aid NMR studies of multi-protein targets. (a) Selective
green) allowing residue-speciﬁc information if a set of residues is labelled. (b) Protein trans-s
ligation (c) Lego-NMR uses different inducible promoters to form a multiprotein complex wi
allowing multi-protein complex handling by NMR.scrambling can occur a number of residues (e. g Alanine, Methio-
nine, Isoleucine, Threonine, Leucine and Valine) were found to be
good reporters for binding and interaction sites (Guo and
Tugarinov, 2009; Ollerenshaw and Tugarinov, 2003; Tugarinov
and Kay, 2004; Tugarinov et al., 2005, 2004; Velyvis et al., 2009).
The concept of segmental isotopic labelling of multi-domain and
fusion proteins is a robust alternative to obtain NMR
spectra (Busche et al., 2009; Cowburn et al., 2004; Muona et al.,
2010). This approach allows the selective labelling in just a
portion of the target protein and it has been demonstrated tomulti-
domain and fusion proteins via protein trans-splicing (PTS) (Mootz,
2009; Muona et al., 2010) using split DNAe intein. PTS is an auto-
catalytic process that works by yielding an active form of the split
intein which catalyses the protein ligation. This works without the
need for refolding protocols or additional residues or modiﬁcations
present in other segmental labelling alternatives. PTS was validated
both in vitro and in cells by using a time-delayed dual-expression
system to achieve effective labelling (Fig. 4b).
Most of the multi-protein complexes are heteromeric assem-
blies of more than one protein and co-expression of all thelabelling can be done separately (e.g one aminoacid at a time, shown in blue, red and
plicing method where split inteines catalyse the NMR-active and NMR-inactive protein
thin the same host. Using this constructs different subunits can be isotopically labelled
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impedes the required detail for structural examination and small
molecule validation. A signiﬁcant drop in yield can occur when
performing in vitro reconstitution of the complex from separately
expressed and co-lysed NMR active and NMR inactive subunits
(Fig. 5a). This is particularly relevant to individual subunits that are
not stable unless in complex with the partner subunit and therefore
do require co-expression to achieve stable and soluble protein
complex (Van Molle et al., 2012). A novel approach termed LEGO-
NMR (Mund et al., 2013) circumvents these limitations by using
induced promoters that are switched on and off at different stages.
This tight regulation is accomplished by having different inducers
and repressors, which prevent leaky expression in both the active
and inactive NMR media (Fig. 4c).
Most importantly all of these approaches preserve the possi-
bility to carry out sequential resonance assignments by triple-
resonance NMR experiments.
3.2. Water(s) and NMR
In multi-protein complexes or PPIs, water is often present and
plays an important role in driving and stabilizing the interactions.
Water molecules can be displaced from the interaction surface or
by acting on the folding transition upon complex assembly. NMR
can address these active roles of waters both qualitatively and
quantitatively.
One of the most standard approaches to measure water-
backbone proton exchange is the CLEAN chemical exchange
(CLEANEX) experiment (Hwang et al., 1998, 1997). The phase-
modulated version of CLEANEX is relatively artefact-free allowingFig. 5. Different labelling schemes and respective spectra in von Hippel-Lindau protein (pVH
complex containing pVHL-EloC-EloB-Cullin2-Rbx1 subunits and bound peptide from substra
pVHL subunit only labelled with 15N (a); and the full complex labelled with 15N (b) and alsaccurate measurements of exchange rates between water and
amide NH protons by magnetization transfer. The experiment is
executed in a difference manner, one spectrum with and another
without water inversion. CLEANEX difference spectra are selective
only to magnetization that is transferred from water protons to
protein amide protons. In this way, easy and qualitative interpre-
tation of the spectra is generally obtained. On the other hand,
effective exchange rates can be obtained by varying the mixing
time in the experiment.
The other face of the coin in water and NMR is water's contri-
bution to the decreasing of spectral crowding. Experiments are
available which explore the concept that, for binding studies, sol-
vent exposed residues are most inﬂuential. Being solvent accessible
these residues can act as reporters and allow the study of inter-
molecular interactions. Whereas buried residues will most likely
not contribute directly for such binding events. This signiﬁcantly
decreases the number of residues in the spectra but still permits
following of binding events effectively. Solvent exposed amide
(SEA) techniques (Lin et al., 2002; Pellecchia et al., 2001) have been
used to study both the local folding/unfolding kinetics and protein
energetic stability. Moreover, rapidly exchanging protons reveal
information about H-bonding, surface dynamics and allostery, all
informative rich parameters to characterise binding events.
3.3. Exploring multi-protein complexes and proteineprotein
interactions with NMR
Using NMR spectroscopy to explore multi-protein complexes
and PPIs is well known to be a laborious task (Bonvin et al., 2005)
and over the years many techniques have been introduced toL) E3 ubiquitin ligase multi-subunit complex. The top panel shows a model for the E3
te Hif-1a. The lower panel shows spectra for the trimeric complex pVHL-EloC-EloB with
o perdeuterated (c).
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hard to think of a greater hallmark to high molecular weight NMR
handling experiment than transverse relaxation-optimised spec-
troscopy (TROSY) (Pervushin et al., 1997). With their introduction
TROSY-basedmethods are established as themost preeminent NMR
approaches presently available (Fig. 5c). By suppressing transverse
relaxation in multidimensional NMR experiments, TROSY has
reduced linewidths for every NMR-active target studied. Transverse
relaxation increases signiﬁcantly with the molecular weight of
proteins. TROSY experiments are based on the constructive use of
interference between themain 1H, 15N and 13C transverse relaxation
rates, dipoleedipole (DD) coupling and chemical shift anisotropy
(CSA). Because these relaxation rates present a molecular size-
independent ratio, a comparable reduction of the overall trans-
verse relaxation rates can be expected for larger proteins. It is the-
oreticized that cancelation of both these pathways is optimal
around 1000 MHz 1H frequencies. Upon decoupling a total cancel-
ation of transverse relaxation effects within a 15Ne1Hmoiety can be
achieved for one of the four multiplet components. The narrow
component observed in this experiment will just have the residual
linewidth coming from DD interactions, which can be further sup-
pressed with perdeuteration (Sattler and Fesik, 1996).
Inclusion of 2H in proteins has an important impact by reducing
magnetization through the spin system of dipolar-coupled protons
(spin diffusion). Using this incorporation to decrease the proton
density in proteins also eradicates spin diffusion pathways,
improving signal-to-noise in the NMR spectra. Additionally, this
incorporation allows identiﬁcation of PPI sites. In an elegant cross-
saturation TROSY-based experiment (Takahashi et al., 2000), a
2He15N uniformly labelled protein is complexed with a non-
labelled interacting protein; taking advantage of higher proton
density, aliphatic protons are irradiated using a radio frequency.
This allows for spin diffusion within the non-labelled protein to
happen instantly throughout the protein, whereas the double-
labelled protein will remain unaffected. If both proteins interact it
is expected that cross-saturation transfer to occur only at the res-
idues in the proteineprotein interface. Simply by measuring the
disappearing residues high-resolution information on the interface
can be mapped into the protein.
Knowledge about interacting protein interfaces is extremely
useful if one is targeting these interactions for disruption or sta-
bilization e.g. using a small molecule (Buckley et al., 2012a, 2012b;
Thiel et al., 2012; Van Molle et al., 2012). Usually this targeting is
hindered by lack of well-deﬁned pockets or grooves on PPIs binding
sites, which ﬁgure a rather more ﬂat character with a relatively
large contact area. Inherently lower LEs are found in PPI-targeting
small molecules and to gain selectivity and afﬁnity more than
one ‘binding subsite’ usually needs to be targeted with the small
molecule. The correlation between successfully targeted PPIs, hit
rates on PPIs and PPI-focused fragment library to PPIs are discussed
to lead the way to successful targeting (Ciulli et al., 2006; Gretes
et al., 2009; Kumari and van der Hoorn, 2011; Mortenson and
Murray, 2011; Stukalov et al., 2012).
PPIs ability to bind small molecules (ligandability) is usually
lower compared to that observed e.g. at buried enzyme active
sites (Edfeldt et al., 2011; Surade and Blundell, 2012; Van Molle
et al., 2012). However NMR screening can deal with this low LE
small molecules, by detecting initial high mM dissociation constant
hits. With a constant paradigm shift, happening both in academy
and industry, in our perspective on what are the most relevant
targets on which to focus drug discovery efforts, it becomes
important that target ligandability is assessed in the best possible
way. By optimizing protein and ligand concentration, hit rate can be
ﬁne-tuned to yield true positive hits, which can be structurally
validated (Dias et al., 2014). Failure on detecting weak but true hitsby some biophysical techniques i.e. false negatives can often
genuinely be happening in this category of targets. NMR based
screening's ability to grasp these starting compounds allows unique
opportunities to succeed in a FBLD campaign.
3.4. Dynamics and NMR
It is well recognized that solution NMR spectroscopy is a
powerful method to study both structural and dynamic properties
of proteins (Fig. 6). The quantitative information of the length and
time scales of protein's internal motions allows unique under-
standing of their biological function (Kern and Zuiderweg, 2003;
Palmer, 2004; Wang et al., 2001). This insight offers knowledge
on protein-ligand (Long et al., 2013) and proteineprotein in-
teractions (Li et al., 2013); as well as insights into allosteric mech-
anisms and by providing a baseline for molecular dynamic
trajectories (Showalter and Brüschweiler, 2007).
Obtaining dynamics parameters from protein backbone 15N
relaxation measurements (Kay et al., 1989) has been a common
experimental practice over the past few decades. Albeit well-
described, some systematic errors are reported, especially for per-
deuterated proteins and when using TROSY (Lakomek et al., 2012).
Nonetheless, this information is extremely useful to describe
picosecond-nanosecond bond vectors motion. Themain techniques
routinely used focus on 15N spin relaxation (longitudinal T1,
transverse T2 and steady-state 1He15N heteronuclear NOE) by
gauging the reorientation of 15NeH bond vectors allowing the
study of backbone dynamics and also every 15N-containing side
chains. This relaxation data is of great value and it informs the rate
of overall molecular tumbling (also known as tc e particularly ac-
curate in the case of isotropic molecular tumbling) or the compo-
nents of the diffusion tensor in the case of anisotropic overall
motion. By comparing ﬂuctuations in local magnetic ﬁeld that lead
to relaxation on the full-length molecule versus residue-speciﬁc
relaxation it is possible to inform on the protein's local internal
motion. A parameter describing the amplitude of internal motions
(S2) (Lipari and Szabo, 1982) and effective rate constant for internal
dynamics can also be readily obtained. This data allows a protein
mapping according to its inherent propensity to exhibit dynamic
behaviour in this timescale and therefore inform on both sample
stability and binding events.
Notwithstanding, events that cause reasonably high amplitude
molecular motions, such as direct protein or ligand interaction or
allosteric regulation, are most likely to fall in the microsecond to
millisecond timescale. Carr-Purcell-Meiboom-Gill (CPMG) relaxa-
tion dispersion (RD) (Mulder et al., 2001; Neudecker et al., 2009;
Vallurupalli et al., 2011) NMR experiments were developed to
tackle these scenarios. These experiments have been brilliantly
applied to protein folding, mostly considering fractional populated
states and transition-state theory yielding both kinetic and struc-
tural information in previously ‘invisible’ protein states (Baldwin
and Kay, 2009; Hansen et al., 2009; Kay, 1998). It is proposed that
all proteins conformations pre-exist to different extents in solution
and the interactions occur by a conformational selection (Boehr
et al., 2009) mechanism. Among other NMR observables, CPMG-
RD allows the characterization of these substates. Measurements
of chemical exchange broadening can support models beyond the
induced-ﬁt hypothesis, for interactions or conformational changes
in which ligand binding or post-translational modiﬁcations may
select one conformation from a pre-existing ensemble.
Interrogation of biomolecular binding events endowing
conformational changes has been reported and the role of pre-
existing equilibria of multiple conformational intermediates can
be interrogated using NMR. The role of dynamics as an entropic
carrier of free energy of allostery (Palmer, 2004) has been inspected
Fig. 6. Different protein dynamics and time scales accessible to NMR spectroscopy.
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change usually happens during the formation of a proteineprotein
interface (Kern and Zuiderweg, 2003; Stone, 2001). Understanding
the fundamentals of conformational entropy of proteins (Boehr
et al., 2009; Frederick et al., 2007; Tzeng and Kalodimos, 2012)
will better inform the elucidation of protein activity and has the
potential to lead to better protein-directed pharmaceuticals.
4. Discussion and new frontiers
NMR spectroscopy is now a well-established technique to
elucidate the structure, interaction and dynamics of molecules in
solution and to guide structure-based lead discovery approaches.
Over the last decade a clear trend has been emerging in the
realization that many of the most attractive drug targets are likely
to be of large size and complexity. Depicting inherently more
complex structures than those historically investigated (e.g.
catalytically-active fragments or single domains of individual pro-
teins), these macromolecular assemblies have proven to be
demanding targets to modern structural biology. The possibility to
handle large molecular weight biomolecules is however now
becoming a reality and it is being diffused to more and more bio-
logical systems. Crucially, it is slowly gaining momentum into drug
discovery projects too. PPIs often fall within this category of chal-
lenging and complex systems, and as a result it is not straightfor-
ward to make progress on them using conventional approaches.
The combination of topological features e.g. ﬂat, extended and
often highly hydrated binding sites bearing few small pockets, and
low ligandability characteristics of PPIs limit their proﬁteering.
Nonetheless, successful campaigns and recent literature examples
have established the high-risk/high-reward status of many PPIs.
With the new paradigm of targeting PPIs in drug discovery, we
predict that NMR approaches will continue to play a crucial role in
facilitating traction against these targets. This requires studying
proteins and obtaining structural information beyond what has
been traditionally considered as one of the main limitations of
NMR, i.e. the size of the molecular target.Understanding what governs protein dynamics in a three-
dimensional manner is still a challenging task. However NMR
spectroscopy has been evolving to better address both protein
dynamics and structure in difﬁcult systems. This has included the
development of ingenious labelling schemes and new pulse se-
quences. Amongst these, we anticipate that TROSY and CPMG-RD
will hold the most promise and potential at pushing the frontiers
of NMR in SBDD. Furthermore, Methyl-TROSY should be considered
as a probing technique to help bringing high molecular weight
targets in focus for FBLD and compound screening, something that
isn't done routinely.
In our opinion, with the technology we have in hand and pro-
spective developments expected in future years, we believe that
the inclusion of millisecond timescale dynamics information pro-
vided by NMR will aid targeting and development of high-quality
chemical probes against multi-protein complexes. This informa-
tion could present structural data on allosteric intermediates and
transient binding sites so that these could then be discovered and
targeted more efﬁciently. It is well documented that these mech-
anisms exist, especially in multi-protein complexes however we
still seem to be one small step away from their structural
comprehension and further usage in lead design. It is well under-
stood that protein conformational dynamics is encoded in their
sequence and structure, and that it is a fundamental requisite for
their biological function (Karplus and Kuriyan, 2005). In moving
targets forward within a given drug discovery pipeline, we predict
that a triad of Structure-Dynamics-Targeting would allow manip-
ulating protein function with increased speciﬁcity and potency.
Acknowledgements
The authors are very grateful to the organizations that funded
their research: the UK Biotechnology and Biological Sciences
Research Council (BBSRC, grants BB/J001201/1 and David Phillips
Fellowship BB/G023123/1 to A.C.), the European Research Council
(ERC-2012-StG-311460 DrugE3CRLs, Starting Grant to A.C.) the
European Commission (Bio-NMR, Project 261863), and the
D.M. Dias, A. Ciulli / Progress in Biophysics and Molecular Biology 116 (2014) 101e112 111Fundaç~ao para a Cie^ncia e a Tecnologia (FCT, SFRH/BD/81735/2011
Studentship to D.M.D.).References
Ayala, I., Sounier, R., Use, N., Gans, P., Boisbouvier, J., 2009. An efﬁcient protocol for
the complete incorporation of methyl-protonated alanine in perdeuterated
protein. J. Biomol. NMR 43, 111e119.
Baldwin, A.J., Kay, L.E., 2009. NMR spectroscopy brings invisible protein states into
focus. Nat. Chem. Biol. 5, 808e814.
Barrett, P.J., Chen, J., Cho, M.-K., Kim, J.-H., Lu, Z., Mathew, S., Peng, D., Song, Y., Van
Horn, W.D., Zhuang, T., S€onnichsen, F.D., Sanders, C.R., 2013. The quiet renais-
sance of protein nuclear magnetic resonance. Biochemistry 52, 1303e1320.
Becattini, B., Pellecchia, M., 2006. SAR by ILOEs: an NMR-based approach to reverse
chemical genetics. Chemistry 12, 2658e2662.
Blundell, T.L., 1996. Structure-based drug design. Nature 384, 23e26.
Bodenhausen, G., Ruben, D.J., 1980. Natural abundance nitrogen-15 NMR by
enhanced heteronuclear spectroscopy. Chem. Phys. Lett. 69, 185e189.
Boehr, D.D., Nussinov, R., Wright, P.E., 2009. The role of dynamic conformational
ensembles in biomolecular recognition. Nat. Chem. Biol. 5, 789e796.
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., Zhang, C.,
Zhang, Y., Habets, G., Burton, E.A., Wong, B., Tsang, G., West, B.L., Powell, B.,
Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K.Y.J., Artis, D.R., Schlessinger, J.,
Su, F., Higgins, B., Iyer, R., D'Andrea, K., Koehler, A., Stumm, M., Lin, P.S., Lee, R.J.,
Grippo, J., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A.,
Chapman, P.B., Flaherty, K.T., Xu, X., Nathanson, K.L., Nolop, K., 2010. Clinical
efﬁcacy of a RAF inhibitor needs broad target blockade in BRAF-mutant mela-
noma. Nature 467, 596e599.
Bonvin, A.M., Boelens, R., Kaptein, R., 2005. NMR analysis of protein interactions.
Curr. Opin. Chem. Biol. 9, 501e508.
Borsi, V., Calderone, V., Fragai, M., Luchinat, C., Sarti, N., 2010. Entropic contribution
to the linking coefﬁcient in fragment based drug design: a case study. J. Med.
Chem. 53, 4285e4289.
Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C.,
Jorgensen, W.L., Ciulli, A., Crews, C.M., 2012a. Small-molecule inhibitors of the
interaction between the E3 Ligase VHL and HIF1a. Angew. Chem. Int. Ed. 51,
11463e11467.
Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J.,
Jorgensen, W.L., Ciulli, A., Crews, C.M., 2012b. Targeting the von HippeleLindau
E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1a interaction.
J. Am. Chem. Soc. 134, 4465e4468.
Busche, A.E.L., Aranko, A.S., Talebzadeh-Farooji, M., Bernhard, F., D€otsch, V., Iwaï, H.,
2009. Segmental isotopic labeling of a central domain in a multidomain protein
by protein trans-splicing using only one robust DnaE intein. Angew. Chem. Int.
Ed. 48, 6128e6131.
Ciulli, A., Williams, G., Smith, A.G., Blundell, T.L., Abell, C., 2006. Probing hot spots at
proteinligand binding sites: a fragment-based approach using biophysical
methods. J. Med. Chem. 49, 4992e5000.
Constantine, K.L., Davis, M.E., Metzler, W.J., Mueller, L., Claus, B.L., 2006. Protein-
ligand NOE matching: a high-throughput method for binding pose evaluation
that does not require protein NMR resonance assignments. J. Am. Chem. Soc.
128, 7252e7263.
Cowburn, D., Shekhtman, A., Xu, R., Ottesen, J.J., Muir, T.W., 2004. Segmental iso-
topic labeling for structural biological applications of NMR. Methods Mol. Biol.
278, 47e56.
Cummings, C.G., Hamilton, A.D., 2010. Disrupting proteineprotein interactions with
non-peptidic, small molecule a-helix mimetics. Curr. Opin. Chem. Biol. 14,
341e346.
Dalvit, C., Vulpetti, A., 2012. Technical and practical aspects of 19F NMR-based
screening: toward sensitive high-throughput screening with rapid deconvolu-
tion. Magn. Reson. Chem. 50, 592e597.
Dalvit, C., Pevarello, P., Tato, M., Veronesi, M., Vulpetti, A., Sundstr€om, M., 2000.
Identiﬁcation of compounds with binding afﬁnity to proteins via magnetization
transfer from bulk water. J. Biomol. NMR 18, 65e68.
Dalvit, C., Fagerness, P.E., Hadden, D.T.A., Sarver, R.W., Stockman, B.J., 2003. Fluo-
rine-NMR experiments for high-throughput screening: theoretical aspects,
practical considerations, and range of applicability. J. Am. Chem. Soc. 125,
7696e7703.
Dias, D.M., Van Molle, I., Baud, M.G.J., Galdeano, C., Geraldes, C.F.G.C., Ciulli, A., 2014.
Is NMR fragment screening ﬁne-tuned to assess druggability of proteineprotein
interactions? ACS Med. Chem. Lett. 5, 23e28.
Diercks, T., Coles, M., Kessler, H., 2001. Applications of NMR in drug discovery. Curr.
Opin. Chem. Biol. 5, 285e291.
Drewry, D.H., Macarron, R., 2010. Enhancements of screening collections to address
areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol.
14, 289e298.
Drysdale, M., Brough, P., 2008. Medicinal chemistry of Hsp90 inhibitors. Curr. Top.
Med. Chem. 8, 859e868.
Edfeldt, F.N.B., Folmer, R.H.A., Breeze, A.L., 2011. Fragment screening to predict
druggability (ligandability) and lead discovery success. Drug. Discov. Today 16,
284e287.
Fernandez, C., Jahnke, W., 2004. New approaches for NMR screening in drug dis-
covery. Drug. Discov. Today 1, 277e283.Frederick, K.K., Marlow, M.S., Valentine, K.G., Wand, A.J., 2007. Conformational
entropy in molecular recognition by proteins. Nature 448, 325e329.
Fry, D.C., 2006. Proteineprotein interactions as targets for small molecule drug
discovery. Biopolymers 84, 535e552.
Fuller, J.C., Burgoyne, N.J., Jackson, R.M., 2009. Predicting druggable binding sites at
the proteineprotein interface. Drug. Discov. Today 14, 155e161.
Gretes, M., Lim, D.C., de Castro, L., Jensen, S.E., Kang, S.G., Lee, K.J., Strynadka, N.C.J.,
2009. Insights into positive and negative requirements for proteineprotein
interactions by crystallographic analysis of the b-lactamase inhibitory proteins
BLIP, BLIP-I, and BLP. J. Mol. Biol. 389, 289e305.
Griswold, I.J., Dahlquist, F.W., 2002. Bigger is better: megadalton protein NMR in
solution. Nat. Struct. Biol. 9, 567e568.
Guan, J.-Y., Keizers, P.H.J., Liu, W.-M., L€ohr, F., Skinner, S.P., Heeneman, E.A.,
Schwalbe, H., Ubbink, M., Siegal, G., 2013. Small-molecule binding sites on
proteins established by paramagnetic NMR spectroscopy. J. Am. Chem. Soc. 135,
5859e5868.
Guo, C., Tugarinov, V., 2009. Identiﬁcation of HN-methyl NOEs in large proteins using
simultaneous amide-methyl TROSY-based detection. J. Biomol. NMR 43, 21e30.
Hajduk, P.J., Greer, J., 2007. A decade of fragment-based drug design: strategic ad-
vances and lessons learned. Nat. Rev. Drug. Discov. 6, 211e219.
Hajduk, P.J., Dinges, J., Schkeryantz, J.M., Janowick, D., Kaminski, M., Tufano, M.,
Augeri, D.J., Petros, A., Nienaber, V., Zhong, P., Hammond, R., Coen, M., Beutel, B.,
Katz, L., Fesik, S.W., 1999. Novel inhibitors of Erm methyltransferases from NMR
and parallel synthesis. J. Med. Chem. 42, 3852e3859.
Hajduk, P.J., Gomtsyan, A., Didomenico, S., Cowart, M., Bayburt, E.K., Solomon, L.,
Severin, J., Smith, R., Walter, K., Holzman, T.F., Stewart, A., McGaraughty, S.,
Jarvis, M.F., Kowaluk, E.A., Fesik, S.W., 2000. Design of adenosine kinase inhibitors
from the NMR-based screening of fragments. J. Med. Chem. 43, 4781e4786.
Hajduk, P.J., Mack, J.C., Olejniczak, E.T., Park, C., Dandliker, P.J., Beutel, B.A., 2004.
SOS-NMR: a saturation transfer NMR-based method for determining the
structures of proteinligand complexes. J. Am. Chem. Soc. 126, 2390e2398.
Hajduk, P.J., Huth, J.R., Fesik, S.W., 2005. Druggability indices for protein targets
derived from NMR-based screening data. J. Med. Chem. 48, 2518e2525.
Hansen, D.F., Feng, H., Zhou, Z., Bai, Y., Kay, L.E., 2009. Selective characterization of
microsecond motions in proteins by NMR relaxation. J. Am. Chem. Soc. 131,
16257e16265.
Harner, M.J., Frank, A.O., Fesik, S.W., 2013. Fragment-based drug discovery using
NMR spectroscopy. J. Biomol. NMR 56, 65e75.
Higueruelo, A.P., Schreyer, A., Bickerton, G.R.J., Pitt, W.R., Groom, C.R., Blundell, T.L.,
2009. Atomic interactions and proﬁle of small molecules disrupting protein-
protein interfaces: the TIMBAL database. Chem. Biol. Drug. Des. 74, 457e467.
Hopkins, A.L., Groom, C.R., 2002. The druggable genome. Nat. Rev. Drug. Discov. 1,
727e730.
Huth, J.R., Sun, C., Sauer, D.R., Hajduk, P.J., 2005. Utilization of NMR-derived frag-
ment leads in drug design. Meth. Enzymol. 394, 548e571.
Hwang, T.L., Mori, S., Shaka, A.J., 1997. Application of phase-modulated CLEAN
chemical EXchange spectroscopy (CLEANEX-PM) to detect water-protein proton
exchange and intermolecular NOEs. J. Am. Chem. Soc. 119, 6203e6204.
Hwang, T.-L., van Zijl, P.C.M., Mori, S., 1998. Accurate quantitation of water-amide
proton exchange rates using the Phase-Modulated CLEAN chemical EXchange
(CLEANEX-PM) approach with a Fast-HSQC (FHSQC) detection scheme.
J. Biomol. NMR 11, 221e226.
Jahnke, W., 2002. Spin labels as a tool to identify and characterize protein - ligand
interactions by NMR spectroscopy. ChemBioChem 3, 167e173.
Jahnke, W., 2007. Perspectives of biomolecular NMR in drug discovery: the blessing
and curse of versatility. J. Biomol. NMR 39, 87e90.
Jahnke, W., Rüdisser, S., Zurini, M., 2001. Spin label enhanced NMR screening. J. Am.
Chem. Soc. 123, 3149e3150.
Jencks, W.P., 1982. On the attribution and additivity of binding energies. Proc. Natl.
Acad. Sci. U. S. A. 78, 4046e4050.
Jubb, H., Higueruelo, A.P., Winter, A., Blundell, T.L., 2012. Structural biology and drug
discovery for proteineprotein interactions. Trends Pharmacol. Sci. 33, 241e248.
Karplus, M., Kuriyan, J., 2005. Molecular dynamics and protein function. Proc. Natl.
Acad. Sci. U. S. A. 102, 6679e6685.
Kay, L.E., 1998. Protein dynamics from NMR. Nat. Struct. Biol. 5. Supplement
513e517.
Kay, L.E., Torchia, D.A., Bax, A., 1989. Backbone dynamics of proteins as studied by
nitrogen-15 inverse detected heteronuclear NMR spectroscopy: application to
staphylococcal nuclease. Biochemistry 28, 8972e8979.
Kern, D., Zuiderweg, E., 2003. The role of dynamics in allosteric regulation. Curr.
Opin. Struct. Biol. 13, 748e757.
Krzeminski, M., Loth, K., Boelens, R., Bonvin, A.M.J.J., 2010. SAMPLEX: automatic
mapping of perturbed and unperturbed regions of proteins and complexes.
BMC Bioinforma. 11, 51.
Kumari, S., van der Hoorn, R.A., 2011. A structural biology perspective on bioactive
small molecules and their plant targets. Curr. Opin. Plant Biol. 14, 480e488.
Kuntz, I.D., Chen, K., Sharp, K.A., Kollman, P.A., 1999. The maximal afﬁnity of ligands.
Proc. Natl. Acad. Sci. U. S. A 96, 9997e10002.
Lakomek, N.-A., Ying, J., Bax, A., 2012. Measurement of 15N relaxation rates in
perdeuterated proteins by TROSY-based methods. J. Biomol. NMR 53, 209e221.
Lepre, C.A., 2011. Practical aspects of NMR-based fragment screening. Methods
Enzymol. 493, 219e239.
Li, Y., Altorelli, N.L., Bahna, F., Honig, B., Shapiro, L., Palmer, A.G., 2013. Mechanism of
E-cadherin dimerization probed by NMR relaxation dispersion. Proc. Natl. Acad.
Sci. U. S. A 110, 16462e16467.
D.M. Dias, A. Ciulli / Progress in Biophysics and Molecular Biology 116 (2014) 101e112112Lin, D., Sze, K.H., Cui, Y., Zhu, G., 2002. Clean SEA-HSQC: a method to map solvent
exposed amides in large non-deuterated proteins with gradient-enhanced
HSQC. J. Biomol. NMR 23, 317e322.
Lipari, G., Szabo, A., 1982. Model-free approach to the interpretation of nuclear
magnetic resonance relaxation in macromolecules. 1. Theory and range of val-
idity. J. Am. Chem. Soc. 104, 4546e4559.
Long, D., Marshall, C.B., Bouvignies, G., Mazhab-Jafari, M.T., Smith, M.J., Ikura, M.,
Kay, L.E., 2013. A comparative CEST NMR study of slow conformational dy-
namics of small GTPases complexed with GTP and GTP analogues. Angew.
Chem. Int. Ed. 52, 10771e10774.
Ludwig, C., Guenther, U.L., 2009. Ligand based NMR methods for drug discovery.
Front. Biosci. 14, 4565e4574.
Mainz, A., Religa, T.L., Sprangers, R., Linser, R., Kay, L.E., Reif, B., 2013. NMR spec-
troscopy of soluble protein complexes at one mega-Dalton and beyond. Angew.
Chem. Int. Ed. 52, 8746e8751.
Makley, L.N., Gestwicki, J.E., 2013. Expanding the number of “druggable” targets:
non-enzymes and protein-protein interactions. Chem. Biol. Drug. Des. 81,
22e32.
Mashalidis, E.H., Sledz, P., Lang, S., Abell, C., 2013. A three-stage biophysical
screening cascade for fragment-based drug discovery. Nat. Protoc. 8,
2309e2324.
Mayer, M., Meyer, B., 1999. Characterization of ligand binding by saturation transfer
difference NMR spectroscopy. Angew. Chem. Int. Ed. 38, 1784e1788.
Mayer, M., Meyer, B., 2001. Group epitope mapping by saturation transfer difference
NMR to identify segments of a ligand in direct contact with a protein receptor.
J. Am. Chem. Soc. 123, 6108e6117.
Mittermaier, A., Kay, L.E., 2006. New tools provide new insights in NMR studies of
protein dynamics. Science 312, 224e228.
Mootz, H.D., 2009. Split inteins as versatile tools for protein semisynthesis.
ChemBioChem 10, 2579e2589.
Mortenson, P.N., Murray, C.W., 2011. Assessing the lipophilicity of fragments and
early hits. J. Comput Aided Mol. Des. 25, 663e667.
Mulder, F.A.A., Skrynnikov, N.R., Hon, B., Dahlquist, F.W., Kay, L.E., 2001. Measure-
ment of slow (msms) time scale dynamics in protein side chains by 15N
relaxation dispersion NMR spectroscopy: application to Asn and Gln residues in
a cavity mutant of T4 lysozyme. J. Am. Chem. Soc. 123, 967e975.
Mund, M., Overbeck, J.H., Ullmann, J., Sprangers, R., 2013. LEGO-NMR spectroscopy:
a method to visualize individual subunits in large heteromeric complexes.
Angew. Chem. Int. Ed. 52, 11401e11405.
Muona, M., Aranko, A.S., Raulinaitis, V., Iwaï, H., 2010. Segmental isotopic labeling of
multi-domain and fusion proteins by protein trans-splicing in vivo and in vitro.
Nat. Protoc. 5, 574e587.
Murray, C.W., Verdonk, M.L., 2002. The consequences of translational and rotational
entropy lost by small molecules on binding to proteins. J. Comput Aided Mol.
Des. 16, 741e753.
Nalepa, G., Rolfe, M., Harper, J.W., 2006. Drug discovery in the ubiq-
uitineproteasome system. Nat. Rev. Drug. Discov. 5, 596e613.
Neudecker, P., Lundstr€om, P., Kay, L.E., 2009. Relaxation dispersion NMR spec-
troscopy as a tool for detailed studies of protein folding. Biophys. J. 96,
2045e2054.
Nooren, I.M.A., Thornton, J.M., 2003. Diversity of protein-protein interactions. EMBO
J. 22, 3486e3492.
Nú~nez, S., Venhorst, J., Kruse, C.G., 2012. Targetedrug interactions: ﬁrst principles
and their application to drug discovery. Drug. Discov. Today 17, 10e22.
Ollerenshaw, J.E., Tugarinov, V., 2003. Methyl TROSY: explanation and experimental
veriﬁcation. Magn. Reson. Chem. 41, 843e852.
Oost, T.K., Sun, C., Armstrong, R.C., Al-Assaad, A.-S., Betz, S.F., Deckwerth, T.L.,
Ding, H., Elmore, S.W., Meadows, R.P., Olejniczak, E.T., Oleksijew, A.,
Oltersdorf, T., Rosenberg, S.H., Shoemaker, A.R., Tomaselli, K.J., Zou, H.,
Fesik, S.W., 2004. Discovery of potent antagonists of the antiapoptotic protein
XIAP for the treatment of cancer. J. Med. Chem. 47, 4417e4426.
Palmer, A.G., 2004. NMR characterization of the dynamics of biomacromolecules.
Chem. Rev. 104, 3623e3640.
Pellecchia, M., Meininger, D., Shen, A.L., Jack, R., Kasper, C.B., Sem, D.S., 2001. SEA-
TROSY (solvent exposed amides with TROSY): a method to resolve the problem
of spectral overlap in very large proteins. J. Am. Chem. Soc. 123, 4633e4634.
Pellecchia, M., Sem, D.S., Wüthrich, K., 2002. NMR in drug discovery. Nat. Rev. Drug.
Discov. 1, 211e219.
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T.L.,
Homans, S.W., Kessler, H., Luchinat, C., Meyer, B., Oschkinat, H., Peng, J.,
Schwalbe, H., Siegal, G., 2008. Perspectives on NMR in drug discovery: a tech-
nique comes of age. Nat. Rev. Drug. Discov. 7, 738e745.
Pervushin, K., Riek, R., Wider, G., Wüthrich, K., 1997. Attenuated T2 relaxation by
mutual cancellation of dipole-dipole coupling and chemical shift anisotropy
indicates an avenue to NMR structures of very large biological macromolecules
in solution. Proc. Natl. Acad. Sci. U. S. A 94, 12366e12371.
Petros, A.M., Huth, J.R., Oost, T., Park, C.-M., Ding, H., Wang, X., Zhang, H., Nimmer, P.,
Mendoza, R., Sun, C., Mack, J., Walter, K., Dorwin, S., Gramling, E., Ladror, U.,
Rosenberg, S.H., Elmore, S.W., Fesik, S.W., Hajduk, P.J., 2010. Discovery of a
potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett.
20, 6587e6591.
Rees, D.C., Congreve, M., Murray, C.W., Carr, R., 2004. Fragment-based lead dis-
covery. Nat. Rev. Drug. Discov. 3, 660e672.Roberts, G.C.K., 2000. Applications of NMR in drug discovery. Drug. Discov. Today 5,
230e240.
Sanchez-Pedregal, V.M., Reese, M., Meiler, J., Blommers, M.J., Griesinger, C.,
Carlomagno, T., 2005. The INPHARMA method: protein-mediated interligand
NOEs for pharmacophore mapping. Angew. Chem. Int. Ed. 44, 4127e4175.
Sattler, M., Fesik, S.W., 1996. Use of deuterium labeling in NMR: overcoming a
sizeable problem. Structure 4, 1245e1249.
Showalter, S.A., Brüschweiler, R., 2007. Validation of molecular dynamics simula-
tions of biomolecules using NMR spin relaxation as benchmarks: application to
the AMBER99SB force ﬁeld. J. Chem. Theory Comput. 3, 961e975.
Shuker, S.B., Hajduk, P.J., Meadows, R.P., Fesik, S.W., 1996. Discovering high-afﬁnity
ligands for proteins: SAR by NMR. Science 274, 1531e1534.
Sledz, P., Silvestre, H.L., Hung, A.W., Ciulli, A., Blundell, T.L., Abell, C., 2010. Opti-
mization of the interligand overhauser effect for fragment linking: application
to inhibitor discovery against Mycobacterium tuberculosis pantothenate syn-
thetase. J. Am. Chem. Soc. 132, 4544e4545.
Sledz, P., Abell, C., Ciulli, A., 2012. Ligand-observed NMR in fragment-based ap-
proaches. In: NMR of Biomolecules: Towards Mechanistic Systems Biology.
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, pp. 264e280.
Smith, M.C., Gestwicki, J.E., 2012. Features of proteineprotein interactions that
translate into potent inhibitors: topology, surface area and afﬁnity. Expert Rev.
Mol. Med. 14, e16.
Stone, M.J., 2001. NMR relaxation studies of the role of conformational entropy in
protein stability and ligand binding. Acc. Chem. Res. 34, 379e388.
Stukalov, A., Superti-Furga, G., Colinge, J., 2012. Deconvolution of targeted pro-
teineprotein interaction maps. J. Proteome Res. 11, 4102e4109.
Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T.,
Rossanese, O.W., Fesik, S.W., 2012. Discovery of small molecules that bind to K-
Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. 51, 6140e6143.
Surade, S., Blundell, T.L., 2012. Structural biology and drug discovery of difﬁcult
targets: the limits of ligandability. Chem. Biol. 19, 42e50.
Takahashi, H., Nakanishi, T., Kami, K., Arata, Y., Shimada, I., 2000. A novel NMR
method for determining the interfaces of large protein-protein complexes. Nat.
Struct. Biol. 7, 220e223.
Thangudu, R.R., Bryant, S.H., Panchenko, A.R., Madej, T., 2012. Modulating pro-
teineprotein interactions with small molecules: the importance of binding
hotspots. J. Mol. Biol. 415, 443e453.
Thiel, P., Kaiser, M., Ottmann, C., 2012. Small-molecule stabilization of protein-
protein interactions: an underestimated concept in drug discovery? Angew.
Chem. Int. Ed. 51, 2012e2018.
Tugarinov, V., Kay, L.E., 2004. An isotope labeling strategy for methyl TROSY spec-
troscopy. J. Biomol. NMR 28, 165e172.
Tugarinov, V., Sprangers, R., Kay, L.E., 2004. Line narrowing in methyl-TROSY using
zero-quantum 1H-13C NMR spectroscopy. J. Am. Chem. Soc. 126, 4921e4925.
Tugarinov, V., Kay, L.E., Ibraghimov, I., Orekhov, V.Y., 2005. High-resolution four-
dimensional 1H-13C NOE spectroscopy using methyl-TROSY, sparse data acqui-
sition, and multidimensional decomposition. J. Am. Chem. Soc. 127, 2767e2775.
Tzeng, S.-R., Kalodimos, C.G., 2012. Protein activity regulation by conformational
entropy. Nature 488, 236e240.
Vallurupalli, P., Bouvignies, G., Kay, L.E., 2011. Increasing the exchange time-scale
that can be probed by CPMG relaxation dispersion NMR. J. Phys. Chem. B 115,
14891e14900.
VanMolle, I., Thomann, A., Buckley, D.L., So, E.C., Lang, S., Crews, C.M., Ciulli, A., 2012.
Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:
Hypoxia inducible factor 1a protein-protein interface. Chem. Biol.19,1300e1312.
Vanwetswinkel, S., Heetebrij, R.J., van Duynhoven, J., Hollander, J.G., Filippov, D.V.,
Hajduk, P.J., Siegal, G., 2005. TINS, target immobilized NMR screening: an efﬁ-
cient and sensitive method for ligand discovery. Chem. Biol. 12, 207e216.
Velyvis, A., Schachman, H.K., Kay, L.E., 2009. Application of methyl-TROSY NMR to
test allosteric models describing effects of nucleotide binding to aspartate
transcarbamoylase. J. Mol. Biol. 387, 540e547.
Wang, C., Grey, J., M., G, Palmer, A., 2001. CPMG sequences with enhanced sensi-
tivity to chemical exchange. J. Biomol. NMR 21, 361e366.
Wells, J.A., McClendon, C.L., 2007. Reaching for high-hanging fruit in drug discovery
at proteineprotein interfaces. Nature 450, 1001e1009.
Williamson, M.P., 2013. Using chemical shift perturbation to characterise ligand
binding. Prog. Nucl. Magn. Reson. Spectrosc. 73, 1e16.
Woodhead, A.J., Angove, H., Carr, M.G., Chessari, G., Congreve, M., Coyle, J.E.,
Cosme, J., Graham, B., Day, P.J., Downham, R., Fazal, L., Feltell, R., Figueroa, E.,
Frederickson, M., Lewis, J., McMenamin, R., Murray, C.W., O'Brien, M.A., Parra, L.,
Patel, S., Phillips, T., Rees, D.C., Rich, S., Smith, D.-M., Trewartha, G., Vinkovic, M.,
Williams, B., Woolford, A.J., 2010. Discovery of (2,4-Dihydroxy-5-
isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]
methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by
fragment based drug design. J. Med. Chem. 53, 5956e5969.
Zhu, Z., Sun, Z.-Y., Ye, Y., Voigt, J., Strickland, C., Smith, E.M., Cumming, J., Wang, L.,
Wong, J., Wang, Y.-S., Wyss, D.F., Chen, X., Kuvelkar, R., Kennedy, M.E.,
Favreau, L., Parker, E., McKittrick, B.A., Stamford, A., Czarniecki, M., Greenlee, W.,
Hunter, J.C., 2010. Discovery of cyclic acylguanidines as highly potent and se-
lective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part Ieinhibitor
design and validation. J. Med. Chem. 53, 951e965.
Zorn, J.A., Wells, J.A., 2010. Turning enzymes on with small molecules. Nat. Chem.
Biol. 6, 179e188.
